154 related articles for article (PubMed ID: 22392423)
21. Pharmacokinetics of once-daily etravirine without and with once-daily darunavir/ritonavir in antiretroviral-naive HIV type-1-infected adults.
DeJesus E; Lalezari JP; Osiyemi OO; Ruane PJ; Ryan R; Kakuda TN; Witek J
Antivir Ther; 2010; 15(5):711-20. PubMed ID: 20710052
[TBL] [Abstract][Full Text] [Related]
22. Increased viral load in a hospitalized patient on treatment with crushed bictegravir/emtricitabine/tenofovir alafenamide: A case report and review of the literature.
Rowe SM; Clary JC; Drummond M; Derrick C; Sanasi K; Bookstaver PB
Am J Health Syst Pharm; 2022 Aug; 79(16):1330-1336. PubMed ID: 35511892
[TBL] [Abstract][Full Text] [Related]
23. The effects of a nucleoside-sparing antiretroviral regimen on the pharmacokinetics of ritonavir-boosted darunavir in HIV type-1-infected patients.
Garvey L; Latch N; Erlwein OW; Mackie NE; Walsh J; Scullard G; McClure MO; Dickinson L; Back D; Winston A
Antivir Ther; 2010; 15(2):213-8. PubMed ID: 20386076
[TBL] [Abstract][Full Text] [Related]
24. Cell disposition of raltegravir and newer antiretrovirals in HIV-infected patients: high inter-individual variability in raltegravir cellular penetration.
Fayet Mello A; Buclin T; Franc C; Colombo S; Cruchon S; Guignard N; Biollaz J; Telenti A; Decosterd LA; Cavassini M
J Antimicrob Chemother; 2011 Jul; 66(7):1573-81. PubMed ID: 21508009
[TBL] [Abstract][Full Text] [Related]
25. Examination of noninferiority, safety, and tolerability of lopinavir/ritonavir and raltegravir compared with lopinavir/ritonavir and tenofovir/ emtricitabine in antiretroviral-naïve subjects: the progress study, 48-week results.
Reynes J; Lawal A; Pulido F; Soto-Malave R; Gathe J; Tian M; Fredrick LM; Podsadecki TJ; Nilius AM
HIV Clin Trials; 2011; 12(5):255-67. PubMed ID: 22180523
[TBL] [Abstract][Full Text] [Related]
26. Pharmacokinetics of the raltegravir/maraviroc/etravirine combination.
Calcagno A; Nozza S; Bonora S; Castagna A; Gonzalez de Requena D; D'Avolio A; Lazzarin A; Di Perri G
J Antimicrob Chemother; 2011 Aug; 66(8):1932-4. PubMed ID: 21642649
[No Abstract] [Full Text] [Related]
27. Switching from twice-daily raltegravir plus tenofovir disoproxil fumarate/emtricitabine to once-daily elvitegravir/cobicistat/emtricitabine/tenofovir disoproxil fumarate in virologically suppressed, HIV-1-infected subjects: 48 weeks data.
Mills A; Crofoot G; Ortiz R; Rashbaum B; Towner W; Ward D; Brinson C; Kulkarni R; Garner W; Ebrahimi R; Cao H; Cheng A; Szwarcberg J
HIV Clin Trials; 2014; 15(2):51-6. PubMed ID: 24710918
[TBL] [Abstract][Full Text] [Related]
28. Blood Telomere Length Changes After Ritonavir-Boosted Darunavir Combined With Raltegravir or Tenofovir-Emtricitabine in Antiretroviral-Naive Adults Infected With HIV-1.
Stella-Ascariz N; Montejano R; Rodriguez-Centeno J; Alejos B; Schwimmer C; Bernardino JI; Rodes B; Allavena C; Hoffmann C; Gisslén M; de Miguel R; Esteban-Cantos A; Wallet C; Raffi F; Arribas JR;
J Infect Dis; 2018 Oct; 218(10):1523-1530. PubMed ID: 29982509
[TBL] [Abstract][Full Text] [Related]
29. Marked increase in etravirine and saquinavir plasma concentrations during atovaquone/proguanil prophylaxis.
Tommasi C; Bellagamba R; Tempestilli M; D'Avolio A; Gallo AL; Ivanovic J; Nicastri E; Pucillo LP; Narciso P
Malar J; 2011 May; 10():141. PubMed ID: 21600016
[TBL] [Abstract][Full Text] [Related]
30. Dual therapy with etravirine plus raltegravir for virologically suppressed HIV-infected patients: a pilot study.
Monteiro P; Perez I; Laguno M; Martínez-Rebollar M; González-Cordon A; Lonca M; Mallolas J; Blanco JL; Gatell JM; Martínez E
J Antimicrob Chemother; 2014 Mar; 69(3):742-8. PubMed ID: 24128667
[TBL] [Abstract][Full Text] [Related]
31. A conventional LC-MS method developed for the determination of plasma raltegravir concentrations.
Takahashi M; Konishi M; Kudaka Y; Okumura N; Hirano A; Terahata N; Banno K; Kaneda T
Biol Pharm Bull; 2008 Aug; 31(8):1601-4. PubMed ID: 18670096
[TBL] [Abstract][Full Text] [Related]
32. Long-term treatment with raltegravir or efavirenz combined with tenofovir/emtricitabine for treatment-naive human immunodeficiency virus-1-infected patients: 156-week results from STARTMRK.
Rockstroh JK; Lennox JL; Dejesus E; Saag MS; Lazzarin A; Wan H; Walker ML; Xu X; Zhao J; Teppler H; Dinubile MJ; Rodgers AJ; Nguyen BY; Leavitt R; Sklar P;
Clin Infect Dis; 2011 Oct; 53(8):807-16. PubMed ID: 21921224
[TBL] [Abstract][Full Text] [Related]
33. Similar efficacy of raltegravir when used with or without a protease inhibitor in treatment-experienced patients.
Skiest DJ; Cohen C; Mounzer K; Haigney Z; Barker D; Gottlieb M; Bellman PC; Dejesus E; Khanlou H; Ruane PJ; Hsiao CB; Abriola K; Rashbaum B; Bellos N; Ward D; Colson A; Santiago F; Habel A; Garb J
HIV Clin Trials; 2011; 12(3):131-40. PubMed ID: 21684853
[TBL] [Abstract][Full Text] [Related]
34. Assessment of the pharmacokinetics of co-administered maraviroc and raltegravir.
Andrews E; Glue P; Fang J; Crownover P; Tressler R; Damle B
Br J Clin Pharmacol; 2010 Jan; 69(1):51-7. PubMed ID: 20078612
[TBL] [Abstract][Full Text] [Related]
35. An HPLC-PDA method for the simultaneous quantification of the HIV integrase inhibitor raltegravir, the new nonnucleoside reverse transcriptase inhibitor etravirine, and 11 other antiretroviral agents in the plasma of HIV-infected patients.
D'Avolio A; Baietto L; Siccardi M; Sciandra M; Simiele M; Oddone V; Bonora S; Di Perri G
Ther Drug Monit; 2008 Dec; 30(6):662-9. PubMed ID: 18824956
[TBL] [Abstract][Full Text] [Related]
36. Raltegravir 1200 mg once daily versus raltegravir 400 mg twice daily, with tenofovir disoproxil fumarate and emtricitabine, for previously untreated HIV-1 infection: a randomised, double-blind, parallel-group, phase 3, non-inferiority trial.
Cahn P; Kaplan R; Sax PE; Squires K; Molina JM; Avihingsanon A; Ratanasuwan W; Rojas E; Rassool M; Bloch M; Vandekerckhove L; Ruane P; Yazdanpanah Y; Katlama C; Xu X; Rodgers A; East L; Wenning L; Rawlins S; Homony B; Sklar P; Nguyen BY; Leavitt R; Teppler H;
Lancet HIV; 2017 Nov; 4(11):e486-e494. PubMed ID: 28918877
[TBL] [Abstract][Full Text] [Related]
37. Effects of raltegravir combined with tenofovir/emtricitabine on body shape, bone density, and lipids in African-Americans initiating HIV therapy.
Young L; Wohl DA; Hyslop WB; Lee YZ; Napravnik S; Wilkin A
HIV Clin Trials; 2015 Oct; 16(5):163-9. PubMed ID: 26249671
[TBL] [Abstract][Full Text] [Related]
38. Pharmacokinetic interactions between etravirine and non-antiretroviral drugs.
Kakuda TN; Schöller-Gyüre M; Hoetelmans RM
Clin Pharmacokinet; 2011 Jan; 50(1):25-39. PubMed ID: 21142266
[TBL] [Abstract][Full Text] [Related]
39. Dual therapy combining raltegravir with etravirine maintains a high level of viral suppression over 96 weeks in long-term experienced HIV-infected individuals over 45 years on a PI-based regimen: results from the Phase II ANRS 163 ETRAL study.
Katlama C; Assoumou L; Valantin MA; Soulié C; Martinez E; Béniguel L; Bouchaud O; Raffi F; Molina JM; Fellahi S; Peytavin G; Marcelin AG; Kolta S; Capeau J; Gibowski S; Cardon F; Reynes J; Costagliola D;
J Antimicrob Chemother; 2019 Sep; 74(9):2742-2751. PubMed ID: 31269208
[TBL] [Abstract][Full Text] [Related]
40. Raltegravir plasma concentrations in treatment-experienced patients receiving salvage regimens based on raltegravir with and without maraviroc coadministration.
Baroncelli S; Villani P; Weimer LE; Ladisa N; Francisci D; Tommasi C; Vullo V; Preziosi R; Cicalini S; Cusato M; Galluzzo C; Floridia M; Regazzi M;
Ann Pharmacother; 2010 May; 44(5):838-43. PubMed ID: 20371753
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
